ArticleTranslational oncology2026
Bibliometric and visual analysis: A comprehensive tracking of global research trends on ablation and tumor immune microenvironment from 2016 to 2025.
Article in Translational oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aims to gain an understanding the relationship between ablation and the tumor immune microenvironment. A bibliometric and visual analysis was conducted on relevant researches in this field over the past decade. MATERIALS AND
methodsAs of February 21, 2026, the research team conducted a literature search using the Web of Science Core Collection (WoSCC) database. Two researchers independently carried out the search. After screening, a total of 5328 papers were selected for analysis. Citespace 6.4.R1, VOSviewer 1.6.18, and Bibliomatrix R software were used for bibliometric analysis and visualization.
resultsAn analysis of research on ablation and the tumor immune microenvironment from 2016 to 2025 shows that China leads the world in the number of published articles and has extensive international cooperation. Chinese research authors, highly cited articles, and research institutions have all performed outstandingly. The study also reviewed the literature on the synergistic effects of ablation and immunotherapy, indicating the dynamic changes in research hotspots in this field.
conclusionThe combination of immunotherapy and ablation is expected to become an effective treatment method for tumors. Ablation has evolved from local destruction to a core tumor treatment strategy that reshapes the immune microenvironment, and its combination with immunotherapy further demonstrates tremendous translational potential and clear clinical value.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.